The European patent covers a plant-based collagen technology designed to support natural tissue regeneration in both aesthetic and reconstructive procedures.
CollPlant Biotechnologies, a regenerative and aesthetic medicine company, announced that the European Patent Office has allowed a patent application related to the company’s injectable fillers and regenerative breast implant candidates. The technologies are being developed for use in aesthetic and reconstructive procedures.
The newly allowed patent application covers CollPlant’s soft tissue fillers and its organ manufacturing technology associated with its regenerative breast implant pipeline. Specifically, the patent outlines a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler, both based on recombinant human collagen (rhCollagen).
The patent is valid until 2041.
Injectable Photocurable Filler
CollPlant’s rhCollagen-based photocurable dermal and soft tissue filler is designed to provide lifting, shaping, and tissue integration, while promoting regeneration. The semiliquid filler is injected and then hardened in place using light illumination through the skin. According to the company, the photocuring process may simplify injection in both subcutaneous and supraperiosteal layers.
As the filler degrades, the formulation is intended to promote regeneration of new tissue in its place.
Regenerative Implant Program
The company is also advancing the development of regenerative breast implants composed of plant-derived rhCollagen and other biocompatible materials. The implants are intended to support natural tissue regeneration without triggering an immune response.
CollPlant is positioning the implants as a potential alternative for both cosmetic enhancement and reconstructive surgeries, including post-mastectomy applications.
Photo caption: A 200cc commercial-size breast implant (in front) from CollPlant’s regenerative program
Photo credit: CollPlant Biotechnologies
